Are Fund Managers Shunning European Biotech?
Despite some recent successes, European biotech remains a less attractive investment opportunity than US biotech, according to most of the panel of European-based health care fund managers interviewed by In Vivo Europe Rx. But all is not lost: some running Europe-only, specialist funds continue to see value in the early stage small-caps.
You may also be interested in...
Epigenomics AG may be a big name in the small world of diagnostic start-ups these days because of its recent IPO, but two-year-old OncoMethylome Sciences SA believes it can give the older company stiff competition in the emerging field of DNA methylation-based cancer markers. The company is developing tests for early diagnosis of cancer and stratification of disease treatments, using highly sensitive, cost-effective DNA methylation technologies.
Chiron's acquisition of PowderJect is the most recent sign that the vaccines industry is coming of age, taking the field's only two mid-sized players up among the top-ranking Big Pharma. This deal was largely about infrastructure. But it suggests any European biotech with a valuable asset--be it product or distribution network--is an attractive takeover target for US firms.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.